Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
March 26 2024 - 8:00AM
Business Wire
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused
on developing first-in-class and best-in-class targeted cancer
therapies, today announced the successful completion of its
purchase of AL102 and related drug candidate AL101 from Ayala
Pharmaceuticals, Inc.
“AL102 is a high-quality asset that complements our existing
pipeline of targeted cancer therapies,” said Clay B. Siegall,
Ph.D., President and Chief Executive Officer of Immunome. “We
believe that AL102 can establish a new standard of care for the
treatment of desmoid tumors. In parallel, we are excited to advance
our preclinical programs towards Phase 1 trials.”
AL102 is an investigational small molecule gamma secretase
inhibitor currently being evaluated in the randomized Phase 3
RINGSIDE international trial for the treatment of desmoid tumors –
a debilitating soft tissue malignancy. AL102 is a potential
once-daily oral treatment for desmoid tumors. Data from clinical
trials have shown AL102 may be more effective in treating desmoid
tumors than OGSIVEO™ (nirogacestat), which recently became the
first treatment approved for desmoid tumors by the U.S. Food and
Drug Administration in November 2023.
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing
first-in-class and best-in-class targeted cancer therapies. Our
portfolio pursues each target with a modality appropriate to its
biology, including immunotherapies, radioligand therapies and ADCs.
We believe that pursuing underexplored targets with appropriate
drug modalities leads to transformative therapies. Our proprietary
memory B cell hybridoma technology allows for the rapid screening
and functional characterization of novel antibodies and
targets.
For more information, visit www.immunome.com or follow us on
Twitter and LinkedIn.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this communication regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities and
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995 (the “PSLRA”). We use words such as
“may,” “could,” “potential,” “will,” “plan,” “believe,” and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions of the PSLRA.
These forward-looking statements include, but are not limited to,
statements regarding Immunome’s belief that AL102 can establish a
new standard of care for the treatment of desmoid tumors; the
potential for AL102 to be a once-daily oral treatment ; and other
statements regarding management’s intentions, plans, beliefs,
expectations or forecasts for the future. No forward-looking
statement can be guaranteed, and actual results may differ
materially from those projected. Such forward-looking statements
are based on Immunome’s expectations and involve risks and
uncertainties; consequently, actual results may differ materially
from those expressed or implied in the statements due to a number
of factors, including, but not limited to, the potential benefit of
the transaction and whether Immunome will realize the intended
value from the transaction, if at all; possible disruptions from
the proposed transaction that could harm Immunome’s businesses;
Immunome’s ability to grow and successfully execute on its business
plan, including the development and commercialization of its
pipeline; changes in the applicable laws or regulations; the
possibility that Immunome may be adversely affected by other
economic, business, and/or competitive factors; the risk that
regulatory approvals for Immunome’s programs and product candidates
are not obtained, are delayed or are subject to unanticipated
conditions; the risk that pre-clinical data may not be predictive
of clinical data; the risk that interim results of a clinical trial
do not necessarily predict final results; potential delays in the
commencement, enrollment and completion of clinical trials and the
reporting of data therefrom; the complexity of numerous regulatory
and legal requirements that Immunome needs to comply with to
operate its business; the reliance on Immunome’s management; the
prior experience and successes of the Immunome’s management team
not being indicative of any future success; uncertainties related
to Immunome’s capital requirements and Immunome’s expected cash
runway; the failure to obtain, adequately protect, maintain or
enforce Immunome’s intellectual property rights; and other risks
and uncertainties indicated from time to time described in
Immunome’s Annual Report on Form 10-K for the year ended December
31, 2022 filed with Securities and Exchange Commission (“SEC”) on
March 16, 2023, Immunome’s Quarterly Report on Form 10-Q for the
quarter ended September 30, 2023 filed with the SEC on November 9,
2023, and in Immunome’s other filings with the SEC. Immunome
cautions that the foregoing list of factors is not exclusive and
not to place undue reliance upon any forward-looking statements
which speak only as of the date made. Moreover, Immunome operates
in a very competitive and rapidly changing environment. New risks
emerge from time to time. Except as required by law, Immunome does
not undertake any obligation to update publicly any forward-looking
statements for any reason after the date of this press release to
conform these statements to actual results or to changes in their
expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240326907197/en/
Investor Contact:
Immunome: Max Rosett Interim Chief Financial Officer
investors@immunome.com
Immunome (NASDAQ:IMNM)
Historical Stock Chart
From Apr 2024 to May 2024
Immunome (NASDAQ:IMNM)
Historical Stock Chart
From May 2023 to May 2024